Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olmesartan medoxomil + probenecid
- Development stage
- Preclinical
- Lead developer
- Daiichi Sankyo Company
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a combination of olmesartan medoxomil, an angiotensin II receptor antagonist used for treating hypertension, and probenecid, a hypouricemic agent used for treating hyperuricemia and gout. This is not a marketed combination product but represents a drug interaction. When co-administered, probenecid increases olmesartan exposure by 40-50% and may increase the occurrence of genitourinary side effects.
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)
Beyond the preview
Go deeper on olmesartan medoxomil + probenecid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olmesartan medoxomil + probenecid.